// App-Quantinova.ai

3146 : Circulating tumor DNA assay performance for detection and monitoring of KRAS mutations in urine from patients with advanced cancers

Researchers

Presenter

  • Takeo Fujii

Principal Investigators

  • Daniel D. Karp

  • Sarina A. Piha-Paul

  • Vivek Subbiah

  • Apostolia M. Tsimberidou

  • Siquing Fu

  • David S. Hong

  • Helen J. Huang

  • Kiran Madwani

  • Debra L. Andrews

  • Saege Hancock

  • Aung Naing

  • Rajyalakshmi Luthra

  • Bryan K. Kee

  • Scott Kopetz

  • Mark G. Erlander

  • Vlada Melnikova

  • Funda Meric-Bernstam

  • Filip Janku

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Tocagen, San Diego, CA.

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Colorectal Cancer

  • Pancreatic cancer

  • Unspecified Cancer

  • Gynaecological cancer

  • Solid malignancies

  • Lung Cancer

Biomarkers

  • KRAS proto-oncogene, GTPase

  • Circulating DNA

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved